ProMIS Neurosciences Inc. PMN:TSX; ARFXF:OTCQB

PMN:TSX; ARFXF:OTCQB

ProMIS Neurosciences Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for best in class treatment of neurodegenerative diseases, in particular, Alzheimer's disease (AD) and ALS. ProMIS Neurosciences' proprietary target discovery engine is based on two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the surface of misfolded proteins. ProMIS has identified five target sites on toxic, misfolded strains of amyloid beta, a known root cause of Alzheimer's, and created five antibodies specific to these targets (without targeting amyloid beta monomer or plaque, known to be related to poor efficacy and side effects). Results of prior clinical trials indicate best in class AD therapy should target specifically toxic, misfolded strains of amyloid beta and not the other forms. ProMIS' AD program is uniquely designed and on track to achieve this goal. The Company's lead antibody product, PMN310 is in late preclinical development, with initiation of clinical trials expected in 2019.

PMN:TSX ARFXF:OTCQB

View Company News

Visit Company Website

Expert Comments:

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment (8/29/18)

The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development.

John Vandermosten, Zacks Small-Cap Research (8/22/18)

"ProMIS Neurosciences Inc. anticipates launching its first in-human trial in 2019 following additional validation of lead candidate, PMN310. . .while still in early stage development, PMN310 makes a compelling case for success and should hold a dominant position in the market if trials are successful and regulatory approval is granted." -Zacks Small-Cap Research

André Uddin, Mackie Research Capital (8/14/18)

"ProMIS Neurosciences Inc. recently identified various mAb candidates against two new targets for neurodegenerative diseases: alpha-synuclein for Parkinson's disease and TDP43 for amyotrophic lateral sclerosis. The company is looking to forge partnerships for these assets; we are not assuming any related deal in our model at this time."

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC (7/11/18)

A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC).

John Vandermosten, Zacks Small-Cap Research (6/27/18)

"We are initiating coverage of ProMIS Neurosciences Inc. with a $7 price target based on our forecast for product sales after a 2027 launch of its lead candidate PMN310 in the United States, European Union and rest of world. . .the company's lead candidate is currently in preclinical development and is expected to begin Phase 1 trials in 2019." -Zacks Small-Cap Research

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase (6/26/18)

This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery.

Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease.

André Uddin, Mackie Research Capital (3/14/18)

"We are maintaining our Speculative Buy rating and our target price of $0.70 on ProMIS Neurosciences Inc. . .the company plans to initiate a single ascending dose, Phase 1 trial with PMN310 in 2019. It is also seeking to forge partnerships with big pharmas for other pipeline candidates."

André Uddin, Mackie Research Capital (1/23/18)

"ProMIS Neurosciences Inc. reported that its PMN310 demonstrated significantly greater binding to toxic amyloid beta oligomers than Biogen's aducanumab in preclinical studies, a positive signal for better efficacy. . .we believe a licensing deal could come in as early as 2018. . .we are maintaining our Speculative Buy rating and increasing our target price to CA$0.70 from CA$0.50 previously."

André Uddin, Mackie Research Capital (1/4/18)

"ProMIS Neurosciences Inc. reported that PMN310 demonstrated no amyloid beta plaque binding in preclinical studies, a positive signal for improved safety. . .in terms of preclinical safety, PMN310 appears to be better than Biogen's aducanumab, which should facilitate a potential licensing deal for PMN310. We believe a licensing deal could come in as early as 2018."

More Expert Comments

André Uddin, Mackie Research Capital (11/13/17) "ProMIS Neurosciences Inc.'s fully diluted Q3/17 EPS of $0.01 compared to $0 last year. . .as of Q3/17E, the company had $3.3M in cash and zero debt on its balance sheet. . .we are maintaining our Speculative Buy rating and target price of CA$0.50/share."

André Uddin, Mackie Research Capital (10/17/17) "ProMIS Neurosciences Inc. announced that its lead Alzheimer's monoclonal antibody (mAb) candidate, PMN310, showed a high degree of selectivity to target amyloid beta oligomers when compared to other amyloid beta-directed mAbs in a preclinical study. . .given the favorable preclinical results, we remain confident that PMN310 should have better efficacy and safety than Biogen's aducanumab and [that] PMN310 has best-in-class potential to treat Alzheimer's."

André Uddin, Mackie Research Capital (9/19/17) "We are initiating coverage of Promis Neurosciences Inc. . .a promising new path for targeting Alzheimer's (AD). A therapy to treat the underlying cause of Alzheimer's disease represents an enormous market opportunity. . .Promis' lead mAb (monoclonal antibody) drug candidate, PMN310, was rationally designed to target toxic amyloid beta (AB) oligomers. AB is a “sticky” peptide (monomer) which clumps together to form toxic oligomers, which can in turn form plaque deposits. . .this newer theory is strongly backed by the Phase 1b success of Biogen's aducanumab which targets toxic AB oligomers. . .we believe this newer AD theory creates a path to develop a unique disease-modifying Alzheimer's treatment, PMN310 which has best-in-class potential."

	Douglas Loe, Echelon Wealth Partners (9/13/17) "ProMIS Neurosciences Inc. announced that a third therapy has been identified for the firm's Alzheimer's disease pipeline. The asset in question is PMN330, a mAb targeting amyloid-beta oligomers, and we assume the mAb is one of many based on CSO Neil Cashman's expertise in developing mAbs that target misfolded protein antigens. . .the asset will join two other identified lead compounds PMN310 and PMN350, with PMN310 still set to be the first lead asset to enter formal clinical trials by 2019."

	Eden Rahim, Next Edge Capital (4/5/17) "ProMIS Neurosciences Inc. is a preclinical company, but it will be going in the clinic over the next year or so. I'm in it because of some of the really important insights it has discovered into the mechanism of action of Alzheimer's disease. What ProMIS has discovered is that the ideal thing to target for Alzheimer's is soluble amyloid beta oligomers. It believes that they are the root cause of Alzheimer's, not the plaque that ultimately settles on the brain. ProMIS has discovered that by focusing on IgG 4 isotype, you can circumvent the inflammation that often comes with monoclonal antibodies. ProMIS has identified six epitopes on protein strains of misfolded amyloid precursor proteins (APPs). APPs are the misfolded proteins that eventually lead to something called fibrils, which eventually clot and form plaques in the brain. ProMIS has discovered that the prion strains of those misfolded proteins carry a marker, called an epitope. It's like a police car with a light on top. ProMIS has developed five murine antibodies that select for those epitopes so antibodies can find them on those misfolded proteins and bind to them. It is actually a pretty profound breakthrough at this level. Again, it's very early stage and preclinical. But ProMIS has selected one of those five antibodies. The drug that it's going to advance, PMN-310, will be its first candidate in clinic. I bought into ProMIS on a financing in the summer of 2015. I'll probably hold it for another 5 or 10 years. It's achieved a lot with very little, and its understanding of the mechanism of action of Alzheimer's is quite significant. I think we'll hear about that over the course of 2017." read more >

Experts Following This Company

	André Uddin – Mackie Research Capital
John Vandermosten, CFA – Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.